4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors

被引：43

作者：

Parmee, ER

He, JF

Mastracchio, A

Edmondson, SD

Colwell, L

Eiermann, G

Feeney, WP

Habulihaz, B

He, HB

Kilburn, R

Leiting, B

Lyons, K

Marsilio, F

Patel, RA

Petrov, A

Di Salvo, J

Wu, JK

Thornberry, NA

Weber, AE

机构：

[1] Merck & Co Inc, Dept Med Chem, Rahway, NJ 07065 USA

[2] Merck & Co Inc, Dept Metab Dis, Rahway, NJ 07065 USA

[3] Merck & Co Inc, Dept Anim Pharmacol, Rahway, NJ 07065 USA

[4] Merck & Co Inc, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA

[5] Merck & Co Inc, Dept Comparat Med, Rahway, NJ 07065 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 01期

关键词：

D O I：

10.1016/j.bmcl.2003.10.016

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Substituted 4-amino cyclohexylglycine analogues were evaluated for DP-IV inhibitory properties. Bis-sulfonamide 15e was an extremely potent 2.6 nM inhibitor of the enzyme with excellent selectivity over all counterscreens. 2,4-Difluorobenzenesulfonamide 15b and 1-naphthyl amide 16b, however, combined an acceptable in vitro profile with good pharmacokinetic properties in the rat, and 15b was orally efficacious at 3 mpk in an OGTT in lean mice. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：43 / 46

页数：4

共 26 条

[1] Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
Ahren, B
Larsson, H
Holst, JJ
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 473 - 478
[2] Ahren B, 2003, DIABETES, V52, pA15
[3] 2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV
Ashworth, DM
Atrash, B
Baker, GR
Baxter, AJ
Jenkins, PD
Jones, DM
Szelke, M
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (10) : 1163 - 1166
[4] Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes
Augustyns, K
Van der Veken, P
Senten, K
Haemers, A
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (04) : 499 - 510
[5] Augustyns K, 1999, CURR MED CHEM, V6, P311
[6] Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, SL
Li, ZH
Ronan, J
Roy, RS
Zhu, L
Jiang, GQ
Liu, F
Woods, J
Zycband, E
Moller, DE
Thornberry, NA
Zhang, BB
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) : 6825 - 6830
[7] CUNNINGHAM DF, 1997, BIOCHIM BIOPHYS ACTA, P1343
[8] Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, DJ
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (01) : 87 - 100
[9] Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, DJ
[J]. GASTROENTEROLOGY, 2002, 122 (02) : 531 - 544
[10] Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors:: Structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity
Friesen, RW
Ducharme, Y
Ball, RG
Blouin, M
Boulet, L
Côté, B
Frenette, R
Girard, M
Guay, D
Huang, Z
Jones, TR
Laliberté, F
Lynch, JJ
Mancini, J
Martins, E
Masson, P
Muise, E
Pon, DJ
Siegl, PKS
Styhler, A
Tsou, NN
Turner, MJ
Young, RN
Girard, Y
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (12) : 2413 - 2426

← 1 2 3 →